Tenax Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Tenax Therapeutics, Inc.
Early engagement with US payers suggests openness to covering a liquid form of riluzole, because the tablet version is proven, but it's impossible to take for many ALS patients, says Italfarmaco subsidiary ITF Pharma.
First quarter VC investments in biopharma set high expectations for the second quarter; Acorda cuts jobs after patent litigation defeat, plus other strategic realignments; no new US IPOs, but Europe has three; and notable follow-on offerings.
Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.
Pipeline Watch has been updated to bring greater depth and detail to a product’s progress through the R&D pipeline, and is now a snapshot of late-stage, Phase II and III clinical trial events for drugs being evaluated by the pharma and biotech industries that is now available to view.
- Medical Devices
- Drug Delivery
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Oxygen Biotherapeutics, Inc.
- Synthetic Blood International, Inc.